Brain metastasis from colorectal cancer: Treatment, survival, and prognosis
Open Access
- 7 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (40) , e30273
Abstract
To investigate the clinical characteristics, survival, prognostic factors, and treatment of brain metastasis (BM) from colorectal cancer (CRC). Twenty-one patients with BM from CRC were retrospectively reviewed. Predictive factors for BM and prognostic factors after the diagnosis of BM were examined by univariate and multivariate COX analysis. The time from the development of extracranial metastases, including lung, bone, and liver, to the occurrence of BM was recorded separately. The median overall survival time was 7 months. In univariate prognostic analysis, median survival with multimodal therapy was better than that with unimodal therapy (10 months vs 3 months, P = .000). In addition, median survival with Karnofsky performance status (KPS) < 70, 1 BM lesion, primary tumor stage of II-III, extracranial lesions < 2, and no extracranial metastasis were much better than the other groups (P < .05 of all). Although there was not a significant difference in median survival between patients receiving combination treatment with bevacizumab and those who did not, treatment with bevacizumab was associated with better survival (10 months vs 5 months, P = .436). The time intervals from bone, liver, and lung metastases to BM were 3, 6.5, and 11 months, respectively. Based on multivariate Cox analysis, KPS and treatment modalities were independent prognosis factors (P = .039 and P = .000, respectively). CRC patients with a high KPS and multimodal treatment have improved survival.Keywords
This publication has 36 references indexed in Scilit:
- Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic FactorsClinical Colorectal Cancer, 2015
- RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancerCancer, 2014
- Prognostic Factors for Patients With Advanced Colorectal Cancer and Symptomatic Brain MetastasesClinical Colorectal Cancer, 2014
- Brain Metastases from Colorectal Cancer: Microenvironment and Molecular MechanismsInternational Journal of Molecular Sciences, 2012
- Clinical Features and Course of Brain Metastases in Colorectal Cancer: An Experience from a Single InstitutionCurrent Oncology, 2012
- Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer centerTumor Biology, 2011
- The incidence and outcome of brain metastases after liver resection for colorectal cancer metastasesColorectal Disease, 2011
- Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain MetastasesJournal of Clinical Oncology, 2009
- Colorectal Cancer Metastatic to the Brain: Time Trends in Presentation and OutcomeOncology, 2009
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007